Field study

Diabetic Medicine

Volumn 23, Issue SUPPL. 3, 2006, Pages 6-12

  Rees, A ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CREATININE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PRAVASTATIN; RETINOID X RECEPTOR; SIMVASTATIN; STATINE DERIVATIVE; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIABETES CONTROL; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE EXACERBATION; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; HEART INFARCTION; HOMOCYSTINURIA; HUMAN; HYPERTRIGLYCERIDEMIA; LUNG EMBOLISM; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; RHABDOMYOLYSIS; STROKE;

ANTILIPEMIC AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; MULTICENTER STUDIES; MULTICENTER STUDIES AS TOPIC; PROCETOFEN; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 33745608714     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.1930_3.x     Document Type: Article

References (40)

1. Haffner SM, Lehto S, Rönnemma T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
2. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. For the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. United Kingdom prospective diabetes study (UKPDS 23). BMJ 1998; 316: 823-828.
3. Vergès B. Diabetic dyslipidaemia: insights for optimising patient management. Curr Med Res Opin 2005; 21: S29-S40.
4. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-749.
5. Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Verges B. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest 2000; 30: 685-694.
6. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
7. JBS 2. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Prepared by: British Cardiac Society, British Hypertension Society, Diabetes UK, Heart UK, Primary Care Cardiovascular Society and Stroke Association. Heart 2005; 91: 1-52.
8. Verges B. Role for fibrate therapy in diabetes: evidence before FIELD. Curr Opin Lipidol 2005; 16: 648-651.
9. Lee CH, Olson P, Evans RM. Mini review: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003; 144: 2201-2207.
10. Stäels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093.
11. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999; 10: 245-257.
12. Bishop-Bailey D, Hla T. Endothelial cells apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta 12,14-prosdtaglandin J2. J Biol Chem 1999; 274: 17042-17048.
13. Zhu Y, Qi C, Jain S, Rao MS, Reddy JK. Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J Biol Chem 1977; 272: 25500-25506.
14. Treuter E, Albrektsen T, Johansson K, Leers J, Gustafsson JA. A regulatory role for RIPI40 in nuclear receptor activation. Mol Endocrinol 1998; 12: 864-881.
15. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Tbromb Vasc Biol 2002; 22: 717-726.
16. Birjmahun RS, Hutten BA, Kastalein JJP, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol increasing compounds. A meta analysis of randomised controlled trials. J Am Coll Cardiol 2005; 45: 185-197.
17. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.
18. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
19. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-825.
20. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85: 37-45.
21. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597-2604.
22. Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, Collins D. Veterans Affairs HDL Intervention Trial (VA-HIT). Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003; 26: 1513-1517.
23. Anonymous. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21-27.
24. Tenebaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165: 1154-1160.
25. Anonymous. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-910.
26. Vakkilanien J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, et al. DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003; 107: 1733-1737.
27. FIELD Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovasc Diabetol 2004; 3: 9.
28. Field Study Investigators. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: baseline characteristics and short-term effects of fenofibrate. Cardiovasc Diabetol 2005; 4: 13.
29. Field Study Investigators. Effects of long term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
30. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001; 101: 671-679.
31. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidaemia (the SAFARI trial). Am J Cardiol 2005; 95: 462-468.
32. ACCORD - Trial Information for Recruitment. www.clinicaltrials.gov/ct/ show/NCT00000620 accessed on 25 January 2006.
33. Wierzbicki AS, Mikhaildis DP, Wray R, Schacter M, Cramb R, Simpson WG, Byrne CB. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003; 19: 155-168.
34. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
35. Grundy SM. The changing face of cardiovascular risk. JACC 2005; 46: 173-175.
36. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
37. Ansquer J-C, Foucher C, Rattier S, Taskinen MR, Steiner G. DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kid Dis 2005; 45: 485-493.
38. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Safety 2006; 5: 145-156.
39. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate and statin versus gemfibrozil and any statin. Am J Cardiol 2005; 95: 120-122.
40. Vergès B. Diabetic dyslipidaemia: insights for optimising patient management. Curr Med Res Opin 2005; 21 (Suppl. 1): S29-S40.